| 000 | 01533 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250518090641.0 | ||
| 264 | 0 | _c20201104 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1744-8301 | ||
| 024 | 7 |
_a10.2217/fon-2019-0647 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFarago, Anna F | |
| 245 | 0 | 0 |
_aLarotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. _h[electronic resource] |
| 260 |
_bFuture oncology (London, England) _cMar 2020 |
||
| 300 |
_a417-425 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOncogene Proteins, Fusion _xgenetics |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptor, trkA _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptor, trkB _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptor, trkC _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDemetri, George D | |
| 773 | 0 |
_tFuture oncology (London, England) _gvol. 16 _gno. 9 _gp. 417-425 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/fon-2019-0647 _zAvailable from publisher's website |
| 999 |
_c30702633 _d30702633 |
||